BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company,...
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast...
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing...
- SHINE Alzheimer’s Trial Expands to European Sites - - SEQUEL Alzheimer’s Trial Awarded Additional NIA Grant to Complete -...
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ:...
Financing led by Wellington Management with participation from other leading healthcare fundsCARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX...
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa...
Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
Ji’an, Jiangxi, China, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and...
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered...
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million...
DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational...
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial...
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson’s disease under the...
– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan: Interim Analysis Now...
Martine Clozel was selected for the Prix Suisse award for her contribution to research, science, and medicine and was presented...
VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the...
REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to...
- The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to...